Clinical trials: Advanced Prostate Carcinoma
Locally Advanced or Metastatic Solid Tumors
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies.
- Trial name
- NCT07730021
- Testing
- ASP388B, Pembrolizumab, Carboplatin
- Where
- 4 sites in United States, Japan
- Volunteers
- 392 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Prostate Cancer
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy…
- Trial name
- ProComD (NCT02234089)
- Testing
- Degarelix, LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)
- Where
- Germany
- Volunteers
- 461 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
This phase II trial studies the effect of androgen ablation therapy with or without niraparib after standard of care radiation therapy in treating patients with prostate cancer that has not spread to other parts of the body…
- Conditions
- Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT04947254
- Testing
- Abiraterone Acetate, Antiandrogen Therapy, Apalutamide
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Tumors, Glioma
A Phase I Study of ECO-4601 in Patients With Advanced Cancer
The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in…
- Conditions
- Tumors, Glioma, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00338026
- Testing
- ECO-4601
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- Thallion Pharmaceuticals
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
This phase I trial tests the safety, side effects and best dose of tin (Sn)-177m-diethylenetriaminepentaacetic acid (DTPA) and how well it works in treating prostate, breast or non-small cell lung cancer that has spread from…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone
- Trial name
- NCT06982222
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Sponsor
- National Cancer Institute (NCI)
Metastatic Castrate Resistant Prostate Cancer
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
Demonstrate detection of ARv7 splice variant transcripts from exosomes in the circulation of MCRPC patients pre and post treatment with selective Androgen pathway inhibitors (i.e. abiraterone and enzalutamide)
- Trial name
- NCT03236688
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
Metastatic Castration-resistant Prostate Cancer
Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer
SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
- Trial name
- NCT05544227
- Testing
- SV-102
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Williams Cancer Foundation
Advanced Cancer
Outcomes of Triaged Family Care in Advanced Cancer
The purpose of this study is to assess the quality of life of patients with advanced cancer and their family caregivers and to evaluate two doses of a family-based program of care versus control.
- Trial name
- FOCUS-Triage (NCT00709176)
- Testing
- Brief FOCUS Program, Extensive FOCUS Program
- Where
- 5 sites in United States
- Volunteers
- 484 people
- Sponsor
- University of Michigan
Advanced Prostate Cancer, Metastatic Prostate Cancer
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer.
- Trial name
- NCT07567846
- Testing
- GDC-1261
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 260 people
- Sponsor
- Genentech, Inc.
Breast Neoplasms, Prostate Neoplasms
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.
- Conditions
- Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma
- Trial name
- NCT03685591
- Testing
- PF-06952229, Enzalutamide
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Pfizer
mCRPC or Advanced/Metastatic Solid Tumors
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.
- Trial name
- NCT07533708
- Testing
- HLX3902
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai Henlius Biotech
Prostate Cancer
Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer
The purpose of this study is to determine if the combination therapy of Hormone, Paclitaxel and Radiation therapy are effective in treatment of locally advanced prostate cancer
- Trial name
- NCT02911350
- Testing
- Hormone Suppressors, Paclitaxel, Radiation Therapy
- Volunteers
- 23 people
- Sponsor
- NYU Langone Health
Prostate Cancer
Personalizing Docetaxel Dosing in Advanced Prostate Cancer
Patients with advanced prostate cancer are often treated with the chemotherapy drug docetaxel. The manufacturers of this drug suggest using the same dose of drug per m² body surface area for all patients.
- Trial name
- PARTNER (NCT04823910)
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Physiomics
Pancreatic Cancer, Breast Cancer
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05311618
- Testing
- NGM438, Pembrolizumab (KEYTRUDA ®)
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Bladder Cancer, Breast Cancer
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm
- Trial name
- NCT00465725
- Testing
- Picoplatin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Poniard Pharmaceuticals
Prostate Cancer, Non Small Cell Lung Cancer
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
OVM-200 will be tested in humans for the first time in Study OVM-200-100. Up to 52 patients aged 18-75 with prostate, lung or ovarian cancer will be enrolled in the Study to find out if OVM-200 is safe to continue studying it in…
- Conditions
- Prostate Cancer, Non Small Cell Lung Cancer, Ovarian Cancer
- Trial name
- NCT05104515
- Testing
- OVM-200
- Where
- 4 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Oxford Vacmedix UK Ltd.
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00104650
- Testing
- AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
- Volunteers
- 111 people
- Sponsor
- Amgen
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
177LuPSMA in Renal Cell Carcinoma
This study aims to evaluate the efficacy and safety of 177Lu-PSMA-617 as a systemic therapy in patients with PSMA-positive advanced clear cell renal cell carcinoma (ccRCC).
- Conditions
- Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer
- Trial name
- LASER (NCT06964958)
- Testing
- 177Lu-PSMA-617
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute